



S1

	Before U46619	After U46619
E_{max}	147.9±5.3	163.2±3.6 *
$LogEC_{50}$	-7.04±0.07	-7.56±0.07 *

1 **Figure S1.** Effects of the thromboxane prostanoid (TP) receptor agonist U46619 on α_1 -
 2 adrenoreceptor-mediated vasoconstriction in S1P2 KO vessels. U46619 (1 nM) was able to
 3 further enhance the contraction responses in spite of the relatively high baseline reactivity of
 4 the S1P2 KO vessels to phenylephrine (PE). *P < 0.05 vs. before U46619 (n=15).

S2

	Before S1P+Fasudil	After S1P+Fasudil
E_{max}	110.7±3.0	109.8±2.9
$LogEC_{50}$	-6.90±0.05	-6.84±0.04

5 **Figure S2.** The effect of fasudil on S1P-induced potentiation of α_1 -adrenoreceptor-mediated
 6 vasoconstriction. Co-administration of the Rho kinase inhibitor fasudil (10 μ M) was also able to
 7 prevent the S1P-induced potentiating effect similar to that of Y-27632. *P < 0.05 vs. before S1P
 8 (n=11).